Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1979 1
1992 1
2003 1
2004 1
2005 3
2006 5
2007 4
2008 5
2009 4
2010 5
2011 4
2012 3
2013 3
2014 2
2015 4
2016 7
2017 9
2018 7
2019 7
2020 14
2021 7
2022 17
2023 6
2024 17
2025 19

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

140 results

Results by year

Filters applied: . Clear all
Page 1
Epigenome editing technologies for discovery and medicine.
McCutcheon SR, Rohm D, Iglesias N, Gersbach CA. McCutcheon SR, et al. Among authors: iglesias n. Nat Biotechnol. 2024 Aug;42(8):1199-1217. doi: 10.1038/s41587-024-02320-1. Epub 2024 Jul 29. Nat Biotechnol. 2024. PMID: 39075148 Review.
Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus.
Werth VP, Furie RA, Romero-Diaz J, Navarra S, Kalunian K, van Vollenhoven RF, Nyberg F, Kaffenberger BH, Sheikh SZ, Radunovic G, Huang X, Clark G, Carroll H, Naik H, Gaudreault F, Meyers A, Barbey C, Musselli C, Franchimont N; LILAC Trial Investigators. Werth VP, et al. N Engl J Med. 2022 Jul 28;387(4):321-331. doi: 10.1056/NEJMoa2118024. N Engl J Med. 2022. PMID: 35939578 Clinical Trial.
Trial of Anti-BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus.
Furie RA, van Vollenhoven RF, Kalunian K, Navarra S, Romero-Diaz J, Werth VP, Huang X, Clark G, Carroll H, Meyers A, Musselli C, Barbey C, Franchimont N; LILAC Trial Investigators. Furie RA, et al. N Engl J Med. 2022 Sep 8;387(10):894-904. doi: 10.1056/NEJMoa2118025. N Engl J Med. 2022. PMID: 36069871 Clinical Trial.
Mechanosensitive genomic enhancers potentiate the cellular response to matrix stiffness.
Cosgrove BD, Bounds LR, Taylor CK, Su AL, Rizzo AJ, Barrera A, Sun T, Safi A, Song L, Whitlow T, Tata A, Iglesias N, Diao Y, Tata PR, Hoffman BD, Crawford GE, Gersbach CA. Cosgrove BD, et al. Among authors: iglesias n. Science. 2025 Sep 25:eadl1988. doi: 10.1126/science.adl1988. Online ahead of print. Science. 2025. PMID: 40997217
Effectiveness of a Novel ω-3 Krill Oil Agent in Patients With Severe Hypertriglyceridemia: A Randomized Clinical Trial.
Mozaffarian D, Maki KC, Bays HE, Aguilera F, Gould G, Hegele RA, Moriarty PM, Robinson JG, Shi P, Tur JF, Lapointe JF, Aziz S, Lemieux P; TRILOGY (Study of CaPre in Lowering Very High Triglycerides) investigators. Mozaffarian D, et al. JAMA Netw Open. 2022 Jan 4;5(1):e2141898. doi: 10.1001/jamanetworkopen.2021.41898. JAMA Netw Open. 2022. PMID: 34989797 Free PMC article. Clinical Trial.
Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis.
Smolen JS, Feist E, Fatenejad S, Grishin SA, Korneva EV, Nasonov EL, Samsonov MY, Fleischmann RM; CREDO2 Group. Smolen JS, et al. N Engl J Med. 2022 Aug 25;387(8):715-726. doi: 10.1056/NEJMoa2201302. N Engl J Med. 2022. PMID: 36001712 Clinical Trial.
Dengue virus NS5 degrades ERC1 during infection to antagonize NF-kB activation.
Gonzalez Lopez Ledesma MM, Costa Navarro G, Pallares HM, Paletta A, De Maio F, Iglesias NG, Gebhard L, Oviedo Rouco S, Ojeda DS, de Borba L, Giraldo M, Rajsbaum R, Ceballos A, Krogan NJ, Shah PS, Gamarnik AV. Gonzalez Lopez Ledesma MM, et al. Among authors: iglesias ng. Proc Natl Acad Sci U S A. 2023 Jun 6;120(23):e2220005120. doi: 10.1073/pnas.2220005120. Epub 2023 May 30. Proc Natl Acad Sci U S A. 2023. PMID: 37252973 Free PMC article.
Silencing repetitive DNA.
Iglesias N, Moazed D. Iglesias N, et al. Elife. 2017 Aug 1;6:e29503. doi: 10.7554/eLife.29503. Elife. 2017. PMID: 28760198 Free PMC article.
Influence of vascular imaging acquisition at local stroke centers on workflows in the drip-n-ship model: a RACECAT post hoc analysis.
Flores A, Garcia-Tornel A, Seró L, Ustrell X, Requena M, Pellisé A, Rodriguez P, Monterde A, Lara L, Gonzalez-de-Echavarri JM, Molina CA, Doncel-Moriano A, Dorado L, Cardona P, Cánovas D, Krupinski J, Más N, Purroy F, Zaragoza-Brunet J, Palomeras E, Cocho D, Garcia J, Colom C, Silva Y, Gomez-Cocho M, Jiménez X, Ros-Roig J, Abilleira S, Pérez de la Ossa N, Ribo M; RACECAT trial investigators. Flores A, et al. J Neurointerv Surg. 2024 Jan 12;16(2):143-150. doi: 10.1136/jnis-2023-020125. J Neurointerv Surg. 2024. PMID: 37068936 Clinical Trial.
140 results